ProKidney Corp. (PROK)Healthcare | Biotechnology | Winston-Salem, United States | NasdaqCM
2.18 USD
+0.23
(11.795%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.14 -0.04 (-0.040%) ⇩ (April 17, 2026, 7:37 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:42 a.m. EDT
PROK is currently a pure momentum trade driven by a recent catalyst (ex-Shield CEO hire, Wainwright buy initiation), but the fundamentals are a trap. The stock is cash-burn-heavy with negative ROEs and a negative book value, making the current 500% rise unsustainable without immediate earnings validation. The options flow confirms a speculative 'pump' into the momentum, but the lack of putflows suggests these traders aren't worried about the imminent debt or financial bleed. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.087583 |
| AutoARIMA | 0.087590 |
| AutoTheta | 0.087742 |
| MSTL | 0.089443 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 4.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.617 |
| Excess Kurtosis | -0.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.342 |
| Revenue per Share | 0.007 |
| Market Cap | 656,685,440 |
| Forward P/E | -2.99 |
| Beta | 1.86 |
| Website | https://prokidney.com |
As of April 19, 2026, 12:42 a.m. EDT: Options flow is heavily skewed towards calls, indicating strong bullish sentiment. For the May '26 expiry, $2 calls show net positive flow (+37.6%). Critically, significant 'long-term' positioning is observed in Jan '28 calls at the $4 strike (2,000 OI vs 300 OI at $3 and 2,500+ OI at $1 ITM). However, downside protection is virtually non-existent; OI for the Jan '28 $4 puts is only 6, creating a massive asymmetry where speculative upside flow is massive compared to negligible downside hedging.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9740791 |
| Address1 | 2,000 Frontis Plaza Boulevard |
| Address2 | Suite 250 |
| All Time High | 14.19 |
| All Time Low | 0.46 |
| Ask | 2.2 |
| Ask Size | 11 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,413,620 |
| Average Daily Volume3 Month | 915,762 |
| Average Volume | 915,762 |
| Average Volume10Days | 1,413,620 |
| Beta | 1.864 |
| Bid | 2.15 |
| Bid Size | 11 |
| Board Risk | 7 |
| Book Value | -7.131 |
| City | Winston-Salem |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.18 |
| Current Ratio | 9.13 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.19 |
| Day Low | 1.98 |
| Debt To Equity | 1.342 |
| Display Name | ProKidney |
| Earnings Timestamp | 1,773,864,000 |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -158,432,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.555 |
| Enterprise To Revenue | 1,517.855 |
| Enterprise Value | 1,355,444,480 |
| Eps Current Year | -0.69992 |
| Eps Forward | -0.72922 |
| Eps Trailing Twelve Months | -0.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0424 |
| Fifty Day Average Change | 0.13760018 |
| Fifty Day Average Change Percent | 0.067371815 |
| Fifty Two Week Change Percent | 197.40791 |
| Fifty Two Week High | 7.13 |
| Fifty Two Week High Change | -4.95 |
| Fifty Two Week High Change Percent | -0.69424963 |
| Fifty Two Week Low | 0.54 |
| Fifty Two Week Low Change | 1.6400001 |
| Fifty Two Week Low Change Percent | 3.0370371 |
| Fifty Two Week Range | 0.54 - 7.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,059,800,000 |
| Float Shares | 93,670,962 |
| Forward Eps | -0.72922 |
| Forward P E | -2.9894958 |
| Free Cashflow | -65,267,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 231 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 893,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.25313 |
| Held Percent Institutions | 0.34445998 |
| Implied Shares Outstanding | 301,231,836 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. |
| Long Name | ProKidney Corp. |
| Market | us_market |
| Market Cap | 656,685,440 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_598380790 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -68,986,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 310,854,961 |
| Number Of Analyst Opinions | 6 |
| Open | 1.99 |
| Operating Cashflow | -120,117,000 |
| Operating Margins | -203.06223 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 336 999 7019 |
| Post Market Change | -0.03999996 |
| Post Market Change Percent | -1.8348606 |
| Post Market Price | 2.14 |
| Post Market Time | 1,776,469,029 |
| Previous Close | 1.95 |
| Price Eps Current Year | -3.1146417 |
| Price Hint | 4 |
| Price To Book | -0.30570748 |
| Price To Sales Trailing12 Months | 735.37006 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.82 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.23 |
| Regular Market Change Percent | 11.7949 |
| Regular Market Day High | 2.19 |
| Regular Market Day Low | 1.98 |
| Regular Market Day Range | 1.98 - 2.19 |
| Regular Market Open | 1.99 |
| Regular Market Previous Close | 1.95 |
| Regular Market Price | 2.18 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,379,527 |
| Return On Assets | -0.26558 |
| Return On Equity | -0.43168 |
| Revenue Growth | 1.961 |
| Revenue Per Share | 0.007 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 141,942,905 |
| Shares Percent Shares Out | 0.1175 |
| Shares Short | 16,683,004 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 15,565,337 |
| Short Name | ProKidney Corp. |
| Short Percent Of Float | 0.16149999 |
| Short Ratio | 21.26 |
| Source Interval | 15 |
| State | NC |
| Symbol | PROK |
| Target High Price | 12.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.75 |
| Total Cash | 270,016,992 |
| Total Cash Per Share | 1.902 |
| Total Debt | 4,036,000 |
| Total Revenue | 893,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.452465 |
| Two Hundred Day Average Change | -0.272465 |
| Two Hundred Day Average Change Percent | -0.111098416 |
| Type Disp | Equity |
| Volume | 1,379,527 |
| Website | https://prokidney.com |
| Zip | 27,103 |